journal article
Mar 21, 2017
Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study
Topics
No keywords indexed for this article. Browse by subject →
References
35
[1]
Terasaki "Human leukocyte antigen antibodies and chronic rejection: from association to causation" Transplantation (2008) 10.1097/tp.0b013e31817c4cb8
[2]
Einecke "Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure" Am J Transplant (2009) 10.1111/j.1600-6143.2009.02799.x
[3]
Lefaucheur "IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury" J Am Soc Nephrol (2016) 10.1681/asn.2014111120
[4]
Loupy "Complement inhibition in HLA-incompatible kidney transplants: persisting antibody-mediated injury despite marked decrease of clinical ABMR" Am J Transplant (2015) 10.1111/ajt.13172
[5]
Everly "Incidence and impact of de novo donor-specific alloantibody in primary renal allografts" Transplantation (2013) 10.1097/tp.0b013e31827d62e3
[6]
Cooper "Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes" Transplantation (2011) 10.1097/tp.0b013e3182139da1
[7]
DeVos "Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation" Kidney Int (2012) 10.1038/ki.2012.190
[8]
Huang "Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation" Clin Transpl (2012)
[9]
Devos "Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection" Transplantation (2014) 10.1097/01.tp.0000438196.30790.66
[10]
Everly "Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss" Am J Transplant (2009) 10.1111/j.1600-6143.2009.02577.x
[11]
Hanaway "Alemtuzumab induction in renal transplantation" N Engl J Med (2011) 10.1056/nejmoa1009546
[12]
Opelz "Influence of race on kidney transplant survival" Transplant Proc (1977)
[13]
Ayanian "The effect of patients' preferences on racial differences in access to renal transplantation" N Engl J Med (1999) 10.1056/nejm199911253412206
[14]
Epstein "Racial disparities in access to renal transplantation - clinically appropriate or due to underuse or overuse?" N Engl J Med (2000) 10.1056/nejm200011233432106
[15]
Matas "OPTN/SRTR 2012 annual data report: kidney" Am J Transplant (2014) 10.1111/ajt.12579
[16]
Ciancio "The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients" Am J Transplant (2003) 10.1034/j.1600-6143.2003.00181.x
[17]
Butkus "Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors" N Engl J Med (1992) 10.1056/nejm199209173271203
[18]
Schweizer "Noncompliance in organ transplant recipients" Transplantation (1990) 10.1097/00007890-199002000-00029
[19]
Neylan "Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group" Transplantation (1998) 10.1097/00007890-199802270-00011
[20]
Racusen "Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection" Am J Transplant (2003) 10.1034/j.1600-6143.2003.00072.x
[21]
Solez "Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’)" Am J Transplant (2007) 10.1111/j.1600-6143.2006.01688.x
[22]
Fine "A proportional hazards model for the subdistribution of a competing risk" Journal of the American Statistical Association (1999) 10.1080/01621459.1999.10474144
[23]
Freitas "The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes" Transplantation (2013) 10.1097/tp.0b013e3182888db6
[24]
Wiebe "Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant" Am J Transplant (2012) 10.1111/j.1600-6143.2012.04013.x
[25]
Heilman "De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation" Transplantation (2014) 10.1097/tp.0000000000000216
[26]
Everly "The impact of HLA-DQ matching on alloantibody production in primary renal transplant recipients" Am J Transplant (2013)
[27]
Denhaerynck "Differences in medication adherence between living and deceased donor kidney transplant patients" Int J Organ Transplant Med (2014)
[28]
Waterman "Modifiable patient characteristics and racial disparities in evaluation completion and living donor transplant" Clin J Am Soc Nephrol (2013) 10.2215/cjn.08880812
[29]
Lentine "Racial variation in medical outcomes among living kidney donors" N Engl J Med (2010) 10.1056/nejmoa1000950
[30]
Sellares "Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence" Am J Transplant (2012) 10.1111/j.1600-6143.2011.03840.x
[31]
Sawinski "Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies" J Am Soc Nephrol (2015) 10.1681/asn.2014010119
[32]
Dieplinger "Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction" Transpl Infect Dis (2015) 10.1111/tid.12467
[33]
Hoshino "Using donor-specific antibodies to monitor the need for immunosuppression" Transplantation (2012) 10.1097/tp.0b013e31824f3d7c
[34]
Tanriover "Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States" Clin J Am Soc Nephrol (2013) 10.2215/cjn.09440912
[35]
Shapiro "Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody" Transplantation (2008) 10.1097/tp.0b013e31816a8a6d
Metrics
15
Citations
35
References
Details
- Published
- Mar 21, 2017
- Vol/Issue
- 30(6)
- Pages
- 566-578
- License
- View
Authors
Funding
Paul I. Terasaki Foundation
Cite This Article
Matthew J. Everly, Kimberly P. Briley, Carl E. Haisch, et al. (2017). Racial differences in incident de novo
donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Transplant International, 30(6), 566-578. https://doi.org/10.1111/tri.12937
Related
You May Also Like
The spectrum of nonadherence with medication in heart, liver, and lung tranplant patients assessed in various ways
Leentje De Bleser, Fabienne Dobbels · 2011
78 citations
10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology ofAspergillusspp. infection in lung transplantation
Maddalena Peghin, Víctor Monforte · 2015
76 citations
Mortality and Causes of Death After Liver Transplantation: Analysis of Sex Differences in a Large Nationwide Cohort
M. Trinidad Serrano, Sergio Sabroso · 2022
60 citations
Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient
Umberto Baccarani, Gian Luigi Adani · 2005
57 citations